138
Participants
Start Date
July 21, 2021
Primary Completion Date
April 3, 2024
Study Completion Date
February 14, 2025
Secukinumab
Secukinumab 150 mg s.c. at BSL, Weeks 1, 2, and 3, followed by administration every 4 weeks starting at Week 4.
Placebo
Placebo 150 mg s.c.at BSL, Weeks 1, 2 and 3, followed by administration every 4 weeks starting at Week 4.
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Changchun
Novartis Investigative Site, Harbin
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Nanjing
Novartis Investigative Site, Nanjing
Novartis Investigative Site, Yangzhou
Novartis Investigative Site, Hefei
Novartis Investigative Site, Hefei
Novartis Investigative Site, Bengbu
Novartis Investigative Site, Linyi
Novartis Investigative Site, Tianjin
Novartis Investigative Site, Zhejiang
Novartis Investigative Site, Wenzhou
Novartis Investigative Site, Nanchang
Novartis Investigative Site, Pingxiang
Novartis Investigative Site, Xiamen
Novartis Investigative Site, Changsha
Novartis Investigative Site, Wuhan
Novartis Investigative Site, Guangzhou
Novartis Investigative Site, Guangzhou
Novartis Investigative Site, Shantou
Novartis Investigative Site, Shenzhen
Novartis Investigative Site, Kunming
Novartis Investigative Site, Ürümqi
Novartis Investigative Site, Baotou
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY